Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cost-effectiveness results from the US Carvedilol Heart Failure Trials Program.

M Vera-Llonch1, J Menzin, R E Richner

  • 1Policy Analysis Inc., Brookline, MA 02445-7629, USA.

The Annals of Pharmacotherapy
|August 4, 2001
PubMed
Summary

Carvedilol, a heart failure treatment, was found to be cost-saving and reduce mortality in clinical trials. This beta-blocker therapy may decrease healthcare costs while improving survival rates for heart failure patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Determinants of imminent fracture risk in postmenopausal women with osteoporosis.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2020
Same author

Predictors of near-term fracture in osteoporotic women aged ≥65 years, based on data from the study of osteoporotic fractures.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2017
Same author

EVOLUTION AND BIFURCATION OF DEVELOPMENTAL PROGRAMS.

Evolution; international journal of organic evolution·2017
Same author

A Real-World Assessment of Annual Multiple Sclerosis Prevalence and Disease-Modifying Drug Treatment Rates Using an Administrative Claims Database.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2016
Same author

Impact of Pulmonary Exacerbations On Eq-5d Measures In Patients With Cystic Fibrosis.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2016
Same author

Work productivity among treatment-naïve patients with genotype 1 chronic hepatitis C infection receiving telaprevir combination treatment.

Journal of viral hepatitis·2014

Area of Science:

  • Cardiovascular Medicine
  • Health Economics

Background:

  • Heart failure (HF) is a significant public health concern associated with high mortality and healthcare costs.
  • Carvedilol is an established beta-blocker approved for HF treatment in the US.

Purpose of the Study:

  • To evaluate the cost-effectiveness of carvedilol in patients with heart failure.
  • To assess the economic impact of carvedilol therapy alongside its mortality benefits.

Main Methods:

  • Economic evaluation conducted alongside the US Carvedilol Heart Failure Trials Program.
  • Analysis of four randomized, double-blind, placebo-controlled clinical trials with a mean follow-up of 6.5 months.
  • Calculation of cost per death averted, considering therapy costs and cardiovascular-related inpatient care.

Related Experiment Videos

Main Results:

  • Carvedilol therapy was associated with lower mean estimated costs of cardiovascular-related inpatient care ($1912 vs. $4463).
  • Mortality was lower in the carvedilol group, resulting in a negative cost per death averted.
  • High probability (0.98) of carvedilol increasing survival and decreasing care costs over 6.5 months.

Conclusions:

  • Carvedilol significantly reduces mortality in patients with heart failure.
  • Carvedilol therapy demonstrates potential cost-saving benefits over a six-month period.
  • The findings support carvedilol as an economically favorable treatment option for heart failure.